Safety Profile

BPC-157 Side Effects & Safety

BPC-157 has a favorable safety profile in animal studies with no serious adverse events reported in rodent toxicology. Human safety data is limited.

Educational content only. This page is compiled from published research for reference and is not medical advice, diagnosis, or treatment. Readers should verify claims against primary sources and consult a qualified healthcare provider before making any health decisions. Full disclaimer.

Side effects by severity

Common1 effect

Injection site reactions

Mild soreness, redness, or warmth at injection sites.

Uncommon3 effects

Headache

Reported anecdotally; mechanism unclear.

Dizziness

Typically mild and transient.

GI upset

Mild nausea or altered bowel patterns reported.

Rare3 effects

Fatigue

Reported in some user anecdotes.

Hypotension

Transient blood pressure reduction reported.

Allergic reactions

Hypersensitivity to the peptide or excipients.

Contraindications

Known hypersensitivity
Active malignancy (due to angiogenic activity — theoretical concern)
Pregnancy and breastfeeding (insufficient safety data)

Drug interactions

Limited published interaction data
Theoretical interaction with other angiogenic factors
Use with NSAIDs may be complementary (preclinical data suggests BPC-157 protects against NSAID GI damage)

Special populations

No human data in pregnancy, pediatrics, or elderly. Not approved in any jurisdiction.

Safety summary

BPC-157 has a clean preclinical safety record with no serious toxicity observed in rodent studies. Human safety data is limited to case reports and user surveys. The theoretical concern about angiogenic stimulation in malignancy remains unresolved.

Frequently asked

Is BPC-157 safe for long-term use?

Long-term human safety data does not exist. Animal studies show no serious adverse effects, but rodent lifespan is limited. Use should be short-term and under medical supervision.

Can BPC-157 cause cancer?

There is no evidence BPC-157 causes cancer. However, its pro-angiogenic mechanism is a theoretical concern in patients with existing malignancy, since tumors depend on angiogenesis.